Drug profile

The FDA adverse-event record for Salmon Oil

45 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Salmon Oil. Species, reactions, and outcomes follow.

#1194 of 2,679
by report volume (all drugs)
45
adverse-event reports
4.4%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Salmon Oil ranks #1182 of 2679 by total reports (45). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1182
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Salmon Oil has 45 reports now versus 45 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Salmon Oil changes

Signature read: Salmon Oil's 4.4% death-coded share is among the lowest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
45
Total Reports
2
Deaths Reported
4.4%
Death-coded share of reports

Active Ingredients

Salmon Oil

Administration Routes

OralUnknown

Species Affected

Dog 42
Cat 3

Most Affected Breeds

Crossbred Canine/dog 8
Retriever - Labrador 5
Shih Tzu 4
Spaniel - Springer English 2
Retriever - Golden 2
Terrier - Yorkshire 2
Schnauzer - Giant 2
Domestic Shorthair 2
Dog (other) 1
Griffon - Brussels 1

Most Reported Reactions

Diarrhoea 9
Other abnormal test result NOS 5
Emesis (multiple) 5
Lack of efficacy - NOS 5
Emesis 4
Vomiting 4
Pruritus 3
Lack of efficacy (endoparasite) - hookworm 3
Lack of efficacy (ectoparasite) - flea 3
Urinary tract infection 3
Not eating 3
Cough 3

Outcome Breakdown

Recovered/Normal
14 (31.1%)
Outcome Unknown
14 (31.1%)
Ongoing
11 (24.4%)
Recovered with Sequela
4 (8.9%)
Euthanized
1 (2.2%)
Died
1 (2.2%)

Salmon Oil: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Salmon Oil (#1194 of 2,679 by report volume); death-coded 4.4%. PlainBreed drug row · death-coded share stamp 4.4% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →